Dr. Lipe is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Connect with other colleagues in the same hospital or clinic
- Search all U.S. specialist profiles and refer a patient
- Read the latest clinical news and earn CME/CEU credits
Office
601 Elmwood Ave
# 320
Rochester, NY 14642Phone+1 585-275-5823Fax+1 585-273-1051- Is this information wrong?
Education & Training
Dartmouth-Hitchcock/Mary Hitchcock Memorial HospitalFellowship, Hematology and Medical Oncology, 2008 - 2011- Dartmouth-Hitchcock/Mary Hitchcock Memorial HospitalResidency, Internal Medicine, 2005 - 2008
Albany Medical CollegeClass of 2005
Certifications & Licensure
NH State Medical License 2008 - Present
NY State Medical License 2015 - 2025
KS State Medical License 2011 - 2016
VT State Medical License 2007 - 2008- American Board of Internal Medicine Hematology
- American Board of Internal Medicine Medical Oncology
Clinical Trials
- Denosumab for Smoldering Multiple Myeloma Start of enrollment: 2019 Apr 19
- Selinexor and Backbone Treatments of Multiple Myeloma Patients Start of enrollment: 2015 Oct 01
Roles: Contact, Principal Investigator
- Selinexor for the Treatment of Intermediate and High-Risk Smoldering Multiple Myeloma Start of enrollment: 2023 Aug 21
Roles: Contact, Principal Investigator
Publications & Presentations
PubMed
- 2 citationsSelinexor-Based Triplet Regimens in Patients With Multiple Myeloma Previously Treated With Anti-CD38 Monoclonal Antibodies.Gary J Schiller, Brea C Lipe, Nizar J Bahlis, Sascha A Tuchman, William I Bensinger, Heather J Sutherland, Suzanne Lentzsch, Muhamed Baljevic, Darrell White, Rami Kotb...> ;Clinical Lymphoma, Myeloma & Leukemia. 2023 Sep 1
- 2 citationsThe roles of bone remodeling in normal hematopoiesis and age-related hematological malignancies.Hengwei Zhang, Jane L Liesveld, Laura M Calvi, Brea C Lipe, Lianping Xing, Michael W Becker, Edward M Schwarz, Shu-Chi A Yeh> ;Bone Research. 2023 Mar 14
- 2 citationsOnychomadesis and palmoplantar keratoderma associated with talquetamab therapy for relapsed and refractory multiple myeloma.Neha Narayan, Benjamin Williams, Brea Lipe, Anna De Benedetto> ;JAAD Case Reports. 2023 Jan 1
- Join now to see all
Abstracts/Posters
- A Phase II Study of Elotuzumab in Combination with Pomalidomide, Bortezomib, and Dexamethasone in Relapsed and Refractory Multiple MyelomaBrea C. Lipe, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
- A Phase 1b/2 Study of Selinexor, Carfilzomib, and Dexamethasone (SKd) in Relapsed/ Refractory Multiple Myeloma (RRMM)Brea C. Lipe, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
- A Phase 2 Study with Minimal Residual Disease (MRD) Driven Adaptive Strategy in Treatment for Newly Diagnosed Multiple Myeloma with Upfront Daratumumab-Based TherapyBrea C. Lipe, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
- Join now to see all
Press Mentions
Survivorship Plan for Multiple MyelomaDecember 3rd, 2022- For Newly Diagnosed Myeloma, Are Four Drugs Better Than Three?December 1st, 2021
- Clinical Trials Gave Wilmot Multiple Myeloma Patient 18 Years - and He's Not Done CountingMay 20th, 2021
- Join now to see all
Hospital Affiliations
Strong Memorial Hospital of the University of RochesterRochester, New York
Canandaigua Veterans Affairs Medical CenterCanandaigua, New York
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
